Heart failure (HF) is a disease that leads to approximately 300,000 fatalities annually in Europe and 250,000 deaths each year in the United States. Type 2 Diabetes Mellitus (T2DM) is a significant ...

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a report published on Saturday. The brokerage issued a hold rating on the biotechnology company’s ...

Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

Liquidia (NASDAQ:LQDA – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report ...

The U.S. FDA has provided advice for Tiakis Biotech's Phase 2 clinical trial of tiprelestat for pulmonary arterial ...

Cannabis dabbing, an increasingly popular way to consume highly concentrated THC, has been linked to pulmonary and neurologic ...

Needham analyst Serge Belanger named Liquidia (LQDA) a top pick for 2025 with a Buy rating and $19 price target The stock was also the ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

No link was found between Competitive Bidding Program implementation and changes in supplemental oxygen use or clinical ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen ’s experimental ...

May 2, 2024 — Blood vessels in the lungs aren't like the others in the body. This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively ...